Medicines optimisation in cancer pai

Not Applicable

Completed

• Conditions: Cancer

• Registration Number: ISRCTN14670659
• Lead Sponsor: niversity of Bradford

Brief Summary

2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30963448 medicines optimisation results (added 24/06/2019) 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29479766 patient interview results (added 24/06/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-01-21
• Study Completion: 2017-04-14
• Last Update Posted: 26 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Stage 1:
1. Aged 16 or over
2. Have advanced cancer and pain
3. Been receiving strong opiods for 2 weeks or more (morphine, fentanyl, buprenorphine, diamorphine, hydromorphone, methadone or oxycodone)
4. Have a good level of spoken and written English (we do not have the resources to employ an interpreter at this time)
5. Have the capacity to provide informed consent to participate
6. Be deemed well enough to take part by their healthcare provider

Stage 3 - as well as the criteria for stage 1 the participants should:
1. Regularly use the pharmacies participating in the study it is not feasible to train all the local pharmacists to provide this service at this point but may be an option for future role out.

Patients with advanced cancer will be defined as:
Those with metastatic cancer (histological, cytological or radiological evidence) AND/OR those receiving anti-cancer therapy with palliative intent

Patients with pain will be defined as:
Those receiving strong opiod analgesic treatment for cancer symptom-related pain AND/OR those receiving analgesics for treatment of cancer therapy-related pain

Exclusion Criteria

Stage 1 and 3:
1. Are unconscious or confused
2. Are, in the opinion of the clinician, unable to understand and complete the interview or questionnaires (due to cognitive impairment for example)
3. Are unwilling to provide informed consent
4. We are not looking to recruit patients in the last days of life so we will exclude those who have received anticipatory medicines in readiness for this

Stage 3 only:
1. They do not use one of the participating pharmacies (although these patients may be included at a later date if the study is expanded)
2. Patients who are deemed ethically inappropriate to approach for example where death is imminent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Current primary outcome measures as of 14/12/2016:<br> The acceptability of the pain medicines consultation to patients, assessed by postal questionnaire two weeks after their final consultation<br><br> Previous primary outcome measures:<br> Feasibility of the process; Timepoint(s): by the end of the study<br>

Secondary Outcome Measures

Name	Time	Method
<br> Added 14/12/2016:<br> The feasibility of delivering the pain medicines consultation to patients with advanced cancer, assessed by how many patients are recruited and whether the consultations can be delivered to them<br>